Mirum Pharmaceuticals, Inc. (MIRM) intrinsic value & 10-year financials
Mirum Pharmaceuticals, Inc. (MIRM) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 128.4% a year to $521.3M, with an average return on invested capital of -43.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $80.14
- Market cap
- $4.0B
- Revenue (FY2025)
- $521.3M
- Revenue growth (8-yr CAGR)
- 128.4%
- ROIC (10-yr avg)
- -43.9%
- Free cash flow (FY2025)
- $54.9M
MIRM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $521.3M | -$23.4M | -$0.47 | $54.9M | -4.2% | -120.9% |
| FY2024 | $336.9M | -$87.9M | -$1.85 | $9.3M | -26.0% | 675.7% |
| FY2023 | $186.4M | -$163.4M | -$4.00 | -$71.1M | -58.6% | -279.0% |
| FY2022 | $77.1M | -$135.7M | -$4.02 | -$120.4M | -170.3% | -121.6% |
| FY2021 | $19.1M | -$84.0M | -$2.77 | -$132.8M | -906.1% | -281.0% |
| FY2020 | $0 | -$103.3M | — | -$89.3M | — | -135.2% |
| FY2019 | — | -$52.6M | — | -$39.6M | — | -45.0% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Mirum Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Mirum Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -60.2% ROIC.
Mirum Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Mirum Pharmaceuticals, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-15.61 per share.